摘要
目的探讨Ⅱ期结直肠癌患者预后影响因素,分析术后辅助化疗的必要性。方法以本院行手术治疗的150例Ⅱ期结直肠癌患者为研究对象,根据5年内肿瘤是否复发分成两组,复发组64例,未复发组86例,分析两组的临床资料,探讨预后的影响因素,分析术后卡培他滨辅助化疗的必要性。结果组间合并肠梗阻、淋巴结数量、肿瘤分化程度、术后辅助化疗存在显著性差异(P<005),多因素分析提示淋巴结检出数量、肿瘤分化程度、术后辅助化疗是影响预后的危险因素。术后辅助化疗108例,5年内复发率37%,生存率85.2%,未行辅助化疗42例,5年内复发率57.1%,生存率71.4%,组间比较差异有统计学意义(P<005)。结论淋巴结数量、肿瘤分化程度、术后辅助化疗是Ⅱ期结直肠癌预后的影响因素,术后卡培他滨辅助化疗可减少复发率,提高生存率。
Objective To investigate the prognostic factors of postoperative patients with stage II colorectal cancer and to analyze the ne- cessity of postoperative adjuvant chemotherapy. Methods 150 patients with stage II eolorectal cancer were selected as research subjects in our hospital. According to the 5-year tumor recurrence, the patients were divided into two groups. There were 64 cases in recurrence group, and 86 cases in non-recurrence group. The clinical data, prognostic factors and the necessity of adjuvant capeeitabine chemotherapy of the two groups were analyzed. Results Intestinal obstruction, lymph node number, the degree of tumor differentiation and adjuvant chemother- apy all showed significant differences between the two groups （P〈 0.05）. The muhiple-factor analysis results indicated that the lymph node number, degree of tumor differentiation and adjuvant chemotherapy were the prognostic risk factors. Among the 108 patients who applied postoperative adjuvant chemotherapy, the 5-year recurrence rate was 37%, and survival rate was g5.2%. However, the 5-year recurrence rate was 57.l% and survival rate was 71.4% among the 42 patients without postoperative adjuvant chemotherapy. The difference had a sta- tistical significance. （P〈0.05） Conclusion The lymph nodes, the degree of tumor differentiation and postoperative adjuvant chemotherapy were the prognostic risk factors for postoperative patients with stage II colorectal cancer. Adjuvant capecitabine chemotherapy could reduce the recurrence rate and improve the survival rate of patients.
出处
《肿瘤药学》
CAS
2017年第2期244-247,共4页
Anti-Tumor Pharmacy
关键词
Ⅱ期结直肠癌
预后影响因素
辅助化疗
Stage II colorectal cancer
Prognostic factors
Adjuvant chemotherapy
